Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC

JTO Clin Res Rep. 2020 Feb 11;1(2):100005. doi: 10.1016/j.jtocrr.2020.100005. eCollection 2020 Jun.

Authors

Ryo Toyozawa¹, Naoki Haratake¹, Gouji Toyokawa², Taichi Matsubara¹, Shinkichi Takamori¹, Naoko Miura¹, Masafumi Yamaguchi¹, Mitsuhiro Takenoyama¹, Takashi Seto¹

Affiliations

¹ Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
² Department of Thoracic Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

No abstract available

Keywords: ALK; Dyslipidemia; Hypertriglyceridemia; Lorlatinib; NSCLC; Pulmonary embolism.

Publication types

Case Reports